Mind Cure Health Inc.
CSE: MCUR

News in the Moment

News Releases

March 31, 2021
MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
March 19, 2021
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
March 15, 2021
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
March 9, 2021
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
March 4, 2021
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
March 3, 2021
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research
March 2, 2021
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
February 22, 2021
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
February 18, 2021
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
February 17, 2021
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
February 16, 2021
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
February 11, 2021
MINDCURE Announces Listing of Warrants
February 10, 2021
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
January 26, 2021
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
January 22, 2021
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
January 21, 2021
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
January 21, 2021
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering
January 12, 2021
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
January 6, 2021
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
December 31, 2020
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
December 29, 2020
Mind Cure Announces Novel Supplement Product to Address Teen Wellness
December 10, 2020
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
December 8, 2020
Mind Cure Announces its Research Program with Psychedelic Compounds
December 2, 2020
Mind Cure Announces Eligibility for DTC Trading
December 1, 2020
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
© 2021 Mind Cure Health Inc.
All rights reserved.

Cookies are used to make this website work and to enhance your experience. To learn more about the types of cookies this website uses, see our Cookie Policy. You can provide consent by clicking the "I Consent" button or by canceling this cookie notice.

Close

Cookies are used to make this website work and to enhance your experience. To learn more about the types of cookies this website uses, see our Cookie Policy. We need your consent to use marketing cookies. Marketing cookies are used to track visitors across websites. The intention is to display ads (via third party services) that are relevant and engaging for individual users. Please select the checkbox below to indicate your consent.

Your cookie preferences have been saved